Harvard Apparatus Regenerative Technology's (HART) Q4 loss per share was $0.34 vs $0.25 a year earlier.
Company recognizes revenue of $22,000.
HART's net loss was $2.6M vs $2M a year earlier.
In December, a fifth successful regenerated human trachea transplant surgery took place.
Early this year, HART held a meeting with the FDA to help the company towards starting trials for its regenerated trachea. The firm has also requested orphan biologics status for the product.
HART had cash on hand of $14M at the end of 2013 and no debt.
HART was spun off from Harvard Bioscience on November 1. (PR)